Drugs / AMG 557
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01493518 | Nov 2011 → May 2013 | psoriasis | Amgen | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02391259 | Nov 2006 → Sep 2011 | systemic lupus erythematosus | Amgen | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02334306 | Jun 2015 → Jan 2018 | Sjogren syndrome | MedImmune LLC | Completed | Missed primary |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01683695 Comparator | Jun 2012 → Mar 2016 | systemic lupus erythematosus | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT01389895 Comparator | Oct 2011 → Mar 2013 | cutaneous lupus erythematosus | Amgen | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00774943 Comparator | Dec 2008 → May 2012 | systemic lupus erythematosus | Amgen | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 557 | “AMG 557/MEDI5872” NCT02334306 ↗ |
| Known as | MEDI5872 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02334306 ↗ |
| Known as | Prezalumab | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109249 ↗ |
| Action | Inhibit | “ICOS ligand inhibitor” CHEMBL2109249 ↗1“ICOSL blockade” PMID 29513931 ↗ May 2018 |
| Modality | Monoclonal antibody | “AMG 557, a human anti-inducible T cell co-stimulator ligand (ICOSL) monoclonal antibody” PMID 27099766 ↗ Apr 2016 |
| Route | Subcutaneous | “administered multiple doses of drug or placebo subcutaneously” NCT00774943 ↗ |
| Target | ICOSLG | “ICOS ligand inhibitor” CHEMBL2109249 ↗ |